Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Closed Independence Day 07-02 16:00:00 EDT

0.7080

-0.0150

-2.07%

盘后0.7080

+0.00000.00%

18:26 EDT

High0.7450	Low0.6710	Vol231.79K
Open0.7450	D1 Closing0.7230	Amplitude10.24%
Mkt Cap25.03M	Tradable Cap19.57M	Total Shares35.35M
T/O164.04K	T/O Rate0.84%	Tradable Shares27.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.708,"timestamp":1783022400000,"preClose":0.723,"halted":0,"volume":231788,"hourTrading":{"tag":"盘后","latestPrice":0.708,"preClose":0.708,"latestTime":"18:26 EDT","volume":38,"amount":26.803,"timestamp":1783031201679,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020746887966805,"floatShares":27646866,"shares":35349800,"eps":-0.436593,"marketStatus":"Closed Independence Day","change":-0.015,"latestTime":"07-02 16:00:00 EDT","open":0.745,"high":0.745,"low":0.671,"amount":164044.8973984,"amplitude":0.102351,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.436593,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.723,"preHourTrading":{"tag":"盘前","latestPrice":0.74,"preClose":0.723,"latestTime":"08:53 EDT","volume":1557,"amount":1152.18,"timestamp":1782996826670,"change":0.017,"changeRate":0.023513,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.708,"preClose":0.708,"latestTime":"18:26 EDT","volume":38,"amount":26.803,"timestamp":1783031201679,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6038278102175126},"requestUrl":"/m/hq/s/NRSN","defaultTab":"news","newsList":[{"id":"2648668810","title":"Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668810?lang=en_us&edition=fundamental","pubTime":"2026-07-02 21:05","pubTimestamp":1782997516,"startTime":"0","endTime":"0","summary":"Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Neurosense Therapeutics Ltd. today and set a price target of $9.00. LeBoyer cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-gets-a-buy-from-noble-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-gets-a-buy-from-noble-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139","NBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647110370","title":"Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647110370","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647110370?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:34","pubTimestamp":1782743682,"startTime":"0","endTime":"0","summary":"BRIEF-Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS StudyJune 29 (Reuters)-Neurosense Therapeutics LtdNRSN.O:NEUROSENSE ACHIEVES PRIMARY ENDPOINT IN PHASE 2B ALS STUDY WITH STATIST","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSNW","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377807","title":"Neurosense Rises as Nerve Disease Drug Shows Promise in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377807?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:51","pubTimestamp":1782741084,"startTime":"0","endTime":"0","summary":"BUZZ-NeuroSense rises as nerve disease drug shows promise in study** U.S.-listed shares of Israel-based drug developer NeuroSense TherapeuticsNRSN.Orise 6.3% to 80 cents** NRSN says its experimental o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N43114F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372744","title":"NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372744","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372744?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:35","pubTimestamp":1782740117,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis has successfully met its prima...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-says-phase-2b-paradigm-study-of-primec-in-als-met-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-says-phase-2b-paradigm-study-of-primec-in-als-met-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372942","title":"Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372942","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372942?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739841,"startTime":"0","endTime":"0","summary":"NeuroSense says Phase 2b ALS trial meets primary endpoint, cuts TDP-43 vs placebo (p=0.0421)NeuroSense reported Phase 2b PARADIGM results showing its PrimeC ALS candidate met the trial’s primary endpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL7J57lw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737261","title":"Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737261?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","NRSNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372188","title":"Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372188?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:30","pubTimestamp":1782739801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3QGJ3T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSNW","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646880302","title":"Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2646880302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646880302?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:20","pubTimestamp":1782393600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA9PSGR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645027612","title":"NeuroSense joins EverythingALS community event on PrimeC data in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2645027612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645027612?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:03","pubTimestamp":1782133397,"startTime":"0","endTime":"0","summary":"NeuroSense to join an EverythingALS community event on PrimeC titled “PrimeC - Connecting the Dots” on June 24, 2026 at 7 p.m. ET.Session led by Prof. Jeffrey Rosenfeld of Loma Linda University; discussion to include NeuroSense CEO Alon Ben-Noon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL1x9rHt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644372150","title":"NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2644372150","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644372150?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:30","pubTimestamp":1781728255,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics CEO Alon Ben-Noon reported buying 250,000 ordinary shares in a private placement.His direct holding rose to 4,534,233 ordinary shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL9QxhkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642822452","title":"Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2642822452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642822452?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:06","pubTimestamp":1781183183,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642829702","title":"NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2642829702","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642829702?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:00","pubTimestamp":1781182851,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics received a South Korean patent covering PrimeC’s composition for amyotrophic lateral sclerosis, including formulation, manufacturing, and use claims.The patent runs through 2042 in South Korea, strengthening IP protection as the company moves toward Phase 3 development.The company has FDA clearance to start its pivotal Phase 3 PARAGON study, following Phase 2b data it described as supporting efficacy and survival.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL4M6Tff:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642421502","title":"Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642421502","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642421502?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:37","pubTimestamp":1781098631,"startTime":"0","endTime":"0","summary":"In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on Neurosense Therapeutics Ltd., with a price target of $3....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-neurosense-therapeutics-ltd-nrsn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-neurosense-therapeutics-ltd-nrsn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498369","title":"NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498369","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498369?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:03","pubTimestamp":1781010213,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics received a Japanese patent grant covering PrimeC, its lead oral drug candidate for amyotrophic lateral sclerosis.The patent covers a ciprofloxacin-celecoxib composition, including the formulation and manufacturing process, with protection running through 2042.The company is preparing to start a Phase 3 PARAGON trial in ALS following FDA clearance, targeting enrollment of about 300 participants.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL4QMLkL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482500","title":"NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482500","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482500?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:06","pubTimestamp":1780923977,"startTime":"0","endTime":"0","summary":"NeuroSense held a meeting with Health Canada on potential regulatory pathways for PrimeC to treat ALS.Talks covered a proposed New Drug Submission strategy, supported by additional clinical, biomarker, long-term outcome data requested by Health Canada.An official Health Canada response is expected in Q3 2026, setting the next milestone for a potential Canadian filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL22NZSv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631877185","title":"NeuroSense prices $600,000 private placement at $0.8 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2631877185","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631877185?lang=en_us&edition=fundamental","pubTime":"2026-04-29 02:30","pubTimestamp":1777401022,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics priced a private placement of USD 600,000 in ordinary shares.Deal calls for sale of 750,000 ordinary shares at USD 0.8 each.Pricing represents a 6.7% premium to April 27 closing price.CEO Alon Ben-Noon, CFO Or Eisenberg, significant existing shareholder each committed USD 200,000.Closing expected during week of May 3, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL9PcSvQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397318","title":"Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397318","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630397318?lang=en_us&edition=fundamental","pubTime":"2026-04-27 22:40","pubTimestamp":1777300833,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-eton-pharmaceuticals-eton-and-ligand-pharma-lgnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-eton-pharmaceuticals-eton-and-ligand-pharma-lgnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LU0128526141.USD","LABU","NRSN","BK4139","BK4581","HCSG","LGND","BK4007","LU0566484027.USD","ETON","LU0029874061.USD","XLV","IE0009354923.USD","XBI","BK4137","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331066","title":"NeuroSense announces departure of Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331066","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331066?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:31","pubTimestamp":1777242705,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) announced on Friday that Dr. Ferenc Tracik will step down from his role as the company’s Chief Medical Officer, effective April 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-announces-departure-of-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-announces-departure-of-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629844273","title":"NeuroSense CMO Ferenc Tracik steps down, effective April 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2629844273","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629844273?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:20","pubTimestamp":1777036849,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics said Chief Medical Officer Ferenc Tracik will step down effective April 27, 2026.Tracik will continue to support NeuroSense as an independent adviser.Advisory work will focus on clinical development and medical strategy for PrimeC, including preparation for an upcoming Pre-NDS meeting with Health Canada.Departure was not tied to any disagreement over operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDLbr2M4n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674919","title":"NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674919?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:20","pubTimestamp":1775481625,"startTime":"0","endTime":"0","summary":"Patent protection in Brazil runs through October 2042.Grant follows prior patents in U.S.  and Australia .Coverage supports PrimeC development in ALS, including planned Phase 3 PARAGON trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLR8q14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":-0.0672},{"period":"1month","weight":-0.115},{"period":"3month","weight":-0.147},{"period":"6month","weight":-0.0922},{"period":"1year","weight":-0.6274},{"period":"ytd","weight":-0.0793}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.030043},{"month":4,"riseRate":0.6,"avgChangeRate":-0.103871},{"month":5,"riseRate":0.4,"avgChangeRate":-0.003304},{"month":6,"riseRate":0.6,"avgChangeRate":0.298631},{"month":7,"riseRate":0,"avgChangeRate":-0.192031},{"month":8,"riseRate":0.5,"avgChangeRate":-0.118473},{"month":9,"riseRate":0.5,"avgChangeRate":0.06987},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction